SCHEMBL18520743

SCHEMBL18520743

Cc1cc2nccc(-c3ccc(Cl)cc3)c2c(C)c1-c1ccc(CN2CCOCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.48
▸ MEN1 O00255 1/20 0.45
▸ USP2 O75604 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ CAMKK2 Q96RR4 3/20 0.44
▸ HRH3 Q9Y5N1 2/20 0.44
▸ CHUK O15111 2/20 0.43
▸ MAPK8 P45983 2/20 0.43
▸ SLC2A1 P11166 1/20 0.43
▸ INSR P06213 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ PIK3CA P42336 2/20 0.41
▸ ACVR1 Q04771 1/20 0.41
▸ LSS P48449 1/20 0.40
▸ SYK P43405 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18520694 0.92 LRRK2 (0.48) LRRK2TSHRCAMKK2HRH3CHUK
SCHEMBL18520383 0.90 PDE4B (0.52) LRRK2MEN1KMT2ACAMKK2HRH3
SCHEMBL18520602 0.90 LRRK2 (0.46) LRRK2CAMKK2HRH3CHUKMAPK8
SCHEMBL18520534 0.88 TNKS (0.45) LRRK2CAMKK2HRH3CHUKMAPK8
SCHEMBL18520742 0.87 PDE2A (0.47) LRRK2USP2TSHRCAMKK2HRH3
SCHEMBL21100744 0.87 HRH3 (0.50) LRRK2CAMKK2HRH3CHUKMAPK8
SCHEMBL18520762 0.86 ABL1 (0.45) LRRK2CAMKK2HRH3CHUKMAPK8
SCHEMBL18520314 0.85 HRH3 (0.41) LRRK2CAMKK2HRH3CHUKMAPK8
SCHEMBL18520309 0.85 CAMKK2 (0.42) LRRK2CAMKK2HRH3CHUKMAPK8
SCHEMBL18520696 0.84 LRRK2 (0.41) LRRK2CAMKK2HRH3CHUKMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745356-B2 Compositions and methods for treating tuberculosis THE BROAD INSTITUTE, INC. (US) 2020-08-18 — — US disclosed
US-20190284140-A1 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS THE BROAD INSTITUTE, INC. 2019-09-19 — — US disclosed
US-10329257-B2 Compositions and methods for treating tuberculosis THE BROAD INSTITUTE, INC. (US) 2019-06-25 — — US disclosed
WO-2017027768-A1 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS THE BROAD INSTITUTE, INC. (US) 2017-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745356-B2 Compositions and methods for treating tuberculosis C5, IFNG, TERT LRRK2 3416/4885MEN1 2513/4885USP2 2912/4885
US-10329257-B2 Compositions and methods for treating tuberculosis C5, IFNG, TERT LRRK2 3416/4885MEN1 2513/4885USP2 2912/4885
US-20190284140-A1 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS C5, IFNG, TERT LRRK2 3416/4885MEN1 2513/4885USP2 2912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback